Top-Rated StocksTop-RatedNASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free TMDX Stock Alerts $142.01 -1.39 (-0.97%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$139.78▼$144.7350-Day Range$84.16▼$144.6752-Week Range$36.42▼$146.12Volume565,171 shsAverage Volume669,887 shsMarket Capitalization$4.68 billionP/E RatioN/ADividend YieldN/APrice Target$133.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside5.7% Downside$133.88 Price TargetShort InterestBearish17.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 8 Articles This WeekInsider TradingSelling Shares$32.04 M Sold Last QuarterProj. Earnings Growth40.26%From $0.77 to $1.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector687th out of 914 stocksElectromedical Equipment Industry16th out of 19 stocks 2.5 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.49% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in TransMedics Group has recently increased by 8.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 2.7 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for TransMedics Group this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows10 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,044,732.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow by 40.26% in the coming year, from $0.77 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -417.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -417.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 33.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesJune 6, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon Sells 2,060 SharesJune 1, 2024 | insidertrades.comDavid Weill Sells 1,193 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockJune 12, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Hits New 52-Week High After Analyst UpgradeJune 10, 2024 | americanbankingnews.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $128.25June 9, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Shares Gap Up Following Analyst UpgradeJune 9, 2024 | americanbankingnews.comTD Cowen Increases TransMedics Group (NASDAQ:TMDX) Price Target to $175.00June 7, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Stock Price Up 3.7%June 7, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Now Covered by Analysts at Cantor FitzgeraldJune 7, 2024 | americanbankingnews.comTamer I. Khayal Sells 2,960 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 21, 2024 | seekingalpha.comTransMedics: Transportation Supporting GrowthMay 17, 2024 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 9, 2024 | finance.yahoo.comInsider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX)May 6, 2024 | seekingalpha.comTransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)May 5, 2024 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comTransMedics Group First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comShould You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now?May 1, 2024 | wsj.comTransMedics Group Inc.May 1, 2024 | fool.comWhy TransMedics Stock Is Soaring TodayMay 1, 2024 | msn.comCrude Oil Down 3%; ISM Manufacturing PMI Falls In AprilMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)May 1, 2024 | markets.businessinsider.comTransMedics Stock Skyrockets, Analysts Call It 'One Of The Best Organic Growth Stories'May 1, 2024 | finance.yahoo.comTransMedics Group Inc (TMDX) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...May 1, 2024 | finance.yahoo.comQ1 2024 Transmedics Group Inc Earnings CallApril 30, 2024 | sfgate.comTransMedics: Q1 Earnings SnapshotApril 30, 2024 | finance.yahoo.comTransMedics Group Inc (TMDX) Surpasses Analyst Revenue Forecasts with Stellar Q1 2024 ResultsSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today6/16/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees584Year FoundedN/APrice Target and Rating Average Stock Price Target$133.88 High Stock Price Target$175.00 Low Stock Price Target$95.00 Potential Upside/Downside-5.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E Ratio184.43 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins-3.43% Pretax Margin-3.92% Return on Equity7.95% Return on Assets1.61% Debt Debt-to-Equity Ratio3.18 Current Ratio9.72 Quick Ratio8.76 Sales & Book Value Annual Sales$241.62 million Price / Sales19.36 Cash Flow$0.14 per share Price / Cash Flow997.68 Book Value$4.20 per share Price / Book33.81Miscellaneous Outstanding Shares32,940,000Free Float30,631,000Market Cap$4.68 billion OptionableOptionable Beta1.95 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.82MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $909.62kMr. Nicholas Corcoran (Age 41)Senior Vice President of Supply Chain & Operations Comp: $812.07kMr. Anil RanganathSenior VP, General Counsel & Corporate SecretaryDr. Tamer I. Khayal M.D. (Age 55)Chief Commercial Officer Comp: $900.11kMr. Mark AndersonSenior Director of Technology DevelopmentMs. Susan GoodmanVice President of Human ResourcesMs. Miriam C. Provost Ph.D. (Age 63)Vice President of Global Regulatory Affairs Comp: $535.93kMore ExecutivesKey CompetitorsMasimoNASDAQ:MASIIntegerNYSE:ITGRLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDInModeNASDAQ:INMDView All CompetitorsInsiders & InstitutionsStephen GordonSold 2,060 sharesTotal: $280,015.80 ($135.93/share)Tamer I KhayalSold 2,960 sharesTotal: $393,976.00 ($133.10/share)Stephen GordonSold 20,000 sharesTotal: $2.83 M ($141.40/share)David WeillSold 1,193 sharesTotal: $168,988.45 ($141.65/share)Cetera Advisors LLCBought 5,302 shares on 5/24/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price target for 2024? 10 Wall Street research analysts have issued 12 month price objectives for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $175.00. On average, they predict the company's share price to reach $133.88 in the next twelve months. This suggests that the stock has a possible downside of 5.7%. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2024? TransMedics Group's stock was trading at $78.93 at the beginning of the year. Since then, TMDX shares have increased by 79.9% and is now trading at $142.01. View the best growth stocks for 2024 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Tuesday, April, 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company earned $96.90 million during the quarter, compared to analysts' expectations of $83.78 million. TransMedics Group had a positive trailing twelve-month return on equity of 7.95% and a negative net margin of 3.43%. The business's quarterly revenue was up 132.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.08) earnings per share. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Principal Healthcare Innovators ETF (BTEC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $390.0 million-$400.0 million, compared to the consensus revenue estimate of $367.0 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.73%), Allspring Global Investments Holdings LLC (2.23%), Allspring Global Investments Holdings LLC (2.23%), First Light Asset Management LLC (2.16%), Wasatch Advisors LP (1.33%) and Bellevue Group AG (1.11%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, Laura Damme, Miriam Provost, Nicholas Corcoran, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMDX) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.